With the rising cost of drugs and increasing regulations, it is essential for organizations to find ways to cut their development costs. Sponsors often focus on achieving regulatory compliance and speeding through early development so they can focus on Phase 3, where they incur the bulk of their development costs. This can cause them to sacrifice on innovative trial design and effective measures for collecting data on the safety and efficacy of a product.
The mission of the 3rd Clinical Trials Phase I and Phase IIA Summit is to provide attendees with the strategies and insight necessary to ensure early stage clinical trials are executed on time and within budget, and to help them explore how to leverage innovative approaches to managing clinical trials from the different therapeutic areas.
Conference - Early Bird Price before September 9th, 2016: USD 1895.00,
Conference - Standard Price after September 9th, 2016: USD 2095.00
Speakers: William Smith, New Orleans Center for Clinical Research, Jim Nissel, Celgene Corporation, George Tonelli, Galmed, Li Zhonggai, Novartis Pharmaceutical, Tatiana Beletskaya, ARENSIA Exploratory Medicine, Tami Crumley, Merck, Mary Westrick, University of Wisconsin, Madison, Howard Greenberg, Janssen (Pharmaceutical Companies of Johnson and Johnson), Laura Vessey, Merck, Amanda Moore, Sage Therapeutics, Richard Clark, Medtronic, Samuel Volchenboum, University of Chicago Graham School, Michelle Combs, Celerion
Sign in to add slides, notes or videos to this session